RM 029
Alternative Names: RM-029Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator REVOLUTION Medicines
- Class Antineoplastics
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (PO)
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 26 May 2022 RM 029 is available for licensing as of 26 May 2022. https://www.revmed.com/about/contact